DVA - JAMES HEARTY Executes Sell Order: Offloads $6.10M In DaVita Stock | Benzinga
JAMES HEARTY, Chief Compliance Officer at DaVita (NYSE:DVA), reported an insider sell on February 21, according to a new SEC filing.
What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday outlined that HEARTY executed a sale of 50,946 shares of DaVita with a total value of $6,100,887.
In the Wednesday's morning session, DaVita's shares are currently trading at $123.0, experiencing a down of 0.0%.
Delving into DaVita's Background
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Financial Milestones: DaVita's Journey
Revenue Growth: DaVita's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, ...